ArticleOncogene2000
The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Epigenetic dysregulation of H19/IGF2 in hepatic cells exposed to toxic metal mixtures in vitro.Scientific reports · 2024Article
- The role of autophagy in cardiovascular disease: Cross-interference of signaling pathways and underlying therapeutic targets.Frontiers in cardiovascular medicine · 2023Review
- The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Review
- Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma.Biomarkers in cancer · 2017Review
- Prohibitin 1 Regulates the H19-Igf2 Axis and Proliferation in Hepatocytes.The Journal of biological chemistry · 2016Article
- Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanism.World journal of hepatology · 2015Review
- The emerging role of Nemo-like kinase (NLK) in the regulation of cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions.Cancer science · 2015Article
- Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets.Molecular and cellular therapies · 2015Article
- Anti-insulin-like growth factor-IIP3 DNAzymes inhibit cell proliferation and induce caspase-dependent apoptosis in human hepatocarcinoma cell lines.Drug design, development and therapy · 2013Article
- Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm?Infectious agents and cancer · 2012Article
- The H19 locus acts in vivo as a tumor suppressor.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology].Der Pathologe · 2007Article
- Review
- Developmental profile of H19 differentially methylated domain (DMD) deletion alleles reveals multiple roles of the DMD in regulating allelic expression and DNA methylation at the imprinted H19/Igf2 locus.Molecular and cellular biology · 2006Article
- FoxA proteins regulate H19 endoderm enhancer E1 and exhibit developmental changes in enhancer binding in vivo.Molecular and cellular biology · 2004Article
- Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.World journal of gastroenterology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of the linked but reciprocally imprinted Igf2 and H19 genes is activated in adult liver in the course of tumor development. By in situ hybridization analysis we have shown that both the Igf2 and H19 RNAs are expressed in the majority of the neoplastic nodules, and that hepatocellular carcinomas are developed in an experimental model of liver carcinogenesis. H19 is also highly activated in smaller and less distinct hyperplastic regions. The few neoplastic areas showing Igf2 but no H19 RNA display loss of the maternally inherited allele at the Igf2/H19 locus. These data are compatible with the existence of a common activation mechanism of these two genes during liver carcinogenesis and with a stronger H19 induction in the pre-neoplastic lesions. By using mice carrying a deletion of the H19 endodermal enhancer, we show that this regulatory element is necessary for the activation of the Igf2 and H19 genes upon induction of liver carcinogenesis. Furthermore, multiple sites of the H19 endodermal enhancer region become hypersensitive to DNase I when the carcinogenesis process is induced. Lastly, liver tumors developed in mice paternally inheriting the H19 enhancer deletion are found to have marked growth delays, increased frequency of apoptotic nuclei, and lack of Igf2 mRNA expression, thus indicating that this regulatory element plays a major role in the progression of liver carcinogenesis, since it is required for the activation of the anti-apoptotic Igf2 gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.